City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push

City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in ​its US initial public offering, as biotech ‌companies press ahead with listings despite market uncertainty.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。